机构:[1]Department of Dermatology, The First Affiliated Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.[2]Department of Dermatology, Guangdong Provincial People's Hospital's Nanhai Hospital, Foshan, Guangdong Province, China.广东省人民医院[3]Department of Dermatology, Yangjiang People's Hospital, Yangjiang, Guangdong Province, China.[4]Department of Dermatology, The Third People's Hospital of Shenzhen, Shenzhen, Guangdong Province, China.深圳市康宁医院深圳市人民医院深圳医学信息中心[5]Department of Dermatology, The Affiliated Shunde Hospital of Jinan University, Foshan City, Guangdong Province, China.
第一作者机构:[1]Department of Dermatology, The First Affiliated Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.[2]Department of Dermatology, Guangdong Provincial People's Hospital's Nanhai Hospital, Foshan, Guangdong Province, China.
共同第一作者:
通讯作者:
通讯机构:[1]Department of Dermatology, The First Affiliated Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.[*1]Department of Dermatology, The First Affiliated Clinical College of Guangzhou University of Chinese Medicine, No.12 Airport Road, Baiyun District, Guangzhou 510405, Guangdong Province, China
推荐引用方式(GB/T 7714):
Yang Botao,Wu Yucai,Chen Yang,et al.MiR-5195-3p targets the PCBP2/PI3K/AKT pathway to inhibit melanoma cell proliferation and migration[J].HELIYON.2023,9(9):doi:10.1016/j.heliyon.2023.e19227.
APA:
Yang Botao,Wu Yucai,Chen Yang,Li Yongshuang,Wang Jinhua...&Liu Jing.(2023).MiR-5195-3p targets the PCBP2/PI3K/AKT pathway to inhibit melanoma cell proliferation and migration.HELIYON,9,(9)
MLA:
Yang Botao,et al."MiR-5195-3p targets the PCBP2/PI3K/AKT pathway to inhibit melanoma cell proliferation and migration".HELIYON 9..9(2023)